USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Advanced microfluidics-based nucleic acid testing and immunoassay platforms are enabling multiplexed detection with rapid turnaround
23-Jun-2022
Global
Technology Research
DA5A-01-00-00-00
HC03554-GL-TR_26656
The rise in both global population and travel is contributing to the increase in spread of infectious diseases. Rapid and accurate identification of the infectious pathogens are imperative for timely intervention, better patient outcomes, and control and management of the spread of the infection. Conventional infectious disease diagnoses are performed in centralized labs; they have a long turnaround time and require expertise. Microfluidics-based infectious disease diagnostics, on the other hand, can enable multiplexed pathogen detection, rapid turnaround, and results at the point of care; they help healthcare providers take quick clinical decisions on treatment or isolation, and enable a lower rate of incidence.
In this report, the microfluidics-based infectious disease diagnostic innovations have been segmented by the property/phenomenon exploited for the isolation or identification. This Frost & Sullivan research service analyzes the drawbacks of conventional infectious disease diagnosis and the benefits of employing microfluidics in infectious disease diagnostics. It also covers growth drivers and the restraints in the micro-/nanofluidic infectious disease diagnostics industry, emerging microfluidic technologies, and companies to action. Technology adoption trends, innovation indicators, and the commercialization voids in the micro-/nanofluidic infectious disease diagnostics are also analyzed. Growth opportunities offered by advanced loop-mediated isothermal amplification platforms, rapid antimicrobial resistance detection platforms, and advanced infectious pathogen biosensors are also discussed. The study also includes an IP landscape analysis of the patents filed over the last 6 years, critical success factors and strategic recommendations.
The spread of infectious diseases is increasing with the rise in global population and global travel. Rapid and accurate identification of the infectious pathogens are imperative for timely interventions enabling better patient outcomes and efficient control and management of the spread of the infection. Conventional infectious disease diagnosis are performed in centralized labs. They have a long turnaround time and requires expertise. Microfluidics-based infectious disease diagnostics can enable multiplexed pathogen detection, rapid turnaround and results at the point of care. It allows healthcare providers to take quick clinical decisions on treatment or isolation, and prevent endemic or epidemic or pandemic. In this report, the microfluidic-based infectious disease diagnostic innovations have been segmented based on the property/phenomena exploited for the isolation or identification. This Frost & Sullivan research service analyzes the drawbacks of conventional infectious disease diagnosis and the benefits of employing microfluidics in infectious disease diagnostics. The growth drivers and the restraints in the micro/nanofluidic infectious disease diagnostics industry are detailed. The emerging microfluidic technologies enabling infectious disease diagnosis and the companies to action are explored. The technology adoption trends, innovation indicators and the commercialization voids in the micro/nanofluidic infectious disease diagnostics are put forth. Growth opportunities offered by advanced loop-mediated isothermal amplification platforms, rapid antimicrobial resistance detection platforms and advanced infectious pathogen biosensors are discussed. The study also includes an IP landscape analysis of the patents filed over the past 6 years. Critical success factors and strategic recommendations are also discussed.
The Strategic Imperative 8™Factors creating Pressure on Growth in the Micro-/nanofluidic Technology for Infectious Disease Control and Management Industry
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on Micro- and Nanofluidic Technology for Infectious Disease Control and Management Industry
About the Growth Pipeline Engine™
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Key Findings
Conventional Infectious Pathogen Detection Methods
Integrated Microfluidic Platforms
Key Growth Metrics
Business Growth Drivers
Technology Growth Drivers
Business Growth Restraints
Technology Growth Restraints
Scope of Analysis
Classification of Microfluidic Technologies
Infectious Pathogens Identified by Commercial Microfluidic Platforms
Technology Segmentation
Microfluidic Nucleic Acid Testing
Microfluidic Nucleic Acid Testing: Competitive Environment
Microfluidic Nucleic Acid Testing: Competitive Environment (continued)
Microfluidic Immunoassay
Microfluidic Immunoassay: Competitive Environment
Microfluidic Immunoassay: Competitive Environment (continued)
Microfluidics-based Electrokinetic Manipulation
Microfluidics-based Electrokinetic Manipulation: Competitive Environment
Microfluidics-enabled Molecular Signature Detection
Microfluidics-enabled Molecular Signature Detection : Competitive Environment
Microfluidics-based Mechanical Characterization
Microfluidics-based Mechanical Characterization: Competitive Environment
Most Adopted Technologies
Microfluidic Platforms Adept at Multiplex Pathogen Detection
M&A Snapshot, 2020–2021
Funding Snapshot, 2020–2022
Funding Snapshot, 2020–2022 (continued)
Top 7 Challenges to Successful Commercialization
Thermo Fisher, MA, US
LexaGene, MA, US
Nan?mix, CA, US
Linear Diagnostics, UK
Biological Dynamics, CA, US
Fudan University, China
Royal Institute of Technology KTH, Sweden
Innovation Themes and IP Activity in the Micro- and Nanofluidic Technology Space
Top Patents
Top Patents (continued)
Top Patents (continued)
Growth Opportunity 1: Loop-Mediated Isothermal Amplification Platforms
Growth Opportunity 1: Loop-mediated Isothermal Amplification Platforms (continued)
Growth Opportunity 2: Rapid Antimicrobial Resistance Detection Platforms
Growth Opportunity 2: Rapid Antimicrobial Resistance Detection Platforms (continued)
Growth Opportunity 3: Advanced Biosensors
Growth Opportunity 3: Advanced Biosensors (continued)
Key Conclusions and Strategic Recommendations
Database of Key Industry Participants
Reference for Technology Readiness level
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
15 Sep 2026 | Global | Market Research
Vendor Profiles: Advanced Wound Care Management Market, Global, 2025
The wound care market is being transformed by advanced technologies and evolving care models that focus on improving patient outcomes and reducing healthcare costs. Innovations such as smart sensor-embedded dressings, artificial intelligence (AI)-based wound imaging systems, enhanced negative pressu...
11 Sep 2026 | Global | Frost Radar
Frost Radar™: Pharmaceutical Commercialization Solutions and Services, 2026
Pharmaceutical commercialization is a multidimensional concept in the successful launch and distribution of a drug. The process includes the development of a pricing strategy that reflects the drug’s value, negotiation with payers to ensure drug cost coverage, regulatory compliance, and the generati...
07 Sep 2026 | Global | Technology Research
Synthetic Antibodies and AI-Optimized Immunotherapies
Artificial intelligence is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion mode...
28 Aug 2026 | Global | Technology Research
Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Digital Solutions, and Medical Imaging Solutions
The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, digital solutions, and medical imaging solutions.The issue features advanced medical devices such as active bioelectr...
27 Aug 2026 | Global | Frost Radar
Frost Radar: AI-Powered Molecular Diagnostics, 2026
AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
The spread of infectious diseases is increasing with the rise in global population and global travel. Rapid and accurate identification of the infectious pathogens are imperative for timely interventions enabling better patient outcomes and efficient control and management of the spread of the infection. Conventional infectious disease diagnosis are performed in centralized labs. They have a long turnaround time and requires expertise. Microfluidics-based infectious disease diagnostics can enable multiplexed pathogen detection, rapid turnaround and results at the point of care. It allows healthcare providers to take quick clinical decisions on treatment or isolation, and prevent endemic or epidemic or pandemic. In this report, the microfluidic-based infectious disease diagnostic innovations have been segmented based on the property/phenomena exploited for the isolation or identification. This Frost & Sullivan research service analyzes the drawbacks of conventional infectious disease diagnosis and the benefits of employing microfluidics in infectious disease diagnostics. The growth drivers and the restraints in the micro/nanofluidic infectious disease diagnostics industry are detailed. The emerging microfluidic technologies enabling infectious disease diagnosis and the companies to action are explored. The technology adoption trends, innovation indicators and the commercialization voids in the micro/nanofluidic infectious disease diagnostics are put forth. Growth opportunities offered by advanced loop-mediated isothermal amplification platforms, rapid antimicrobial resistance detection platforms and advanced infectious pathogen biosensors are discussed. The study also includes an IP landscape analysis of the patents filed over the past 6 years. Critical success factors and strategic recommendations are also discussed.
| Deliverable Type | Technology Research |
|---|---|
| Author | Sneha Maria Mariawilliam |
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Podcast | No |
| WIP Number | DA5A-01-00-00-00 |
Micro- and Nanofluidic Technology Innovations for Infectious Disease Control and Management
$4,950.00
Special Price $3,712.50 save 25 %